NCT04655625已完成2 期
A Randomized, Double-blind, Placebo Controlled Phase II / III Study to Assess Safety, Immunogenicity and Efficacy of Twice Dosing of Intramuscular AG0302-COVID19 (2mg) in Healthy Adults
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AnGes, Inc.
- 入组人数
- 500
- 试验地点
- 16
- 主要终点
- Incidence of Treatment-Emergent Adverse Events
研究概览
简要总结
This study will assess the safety, immunogenicity and efficacy of AG0302-COVID19 in healthy adult volunteers.
详细描述
This is a Phase II /III, multi-center, randomized, double-blind, placebo controlled trial. Approximately 500 healthy volunteers, male or female, aged 18 years or older, will be randomized to one of the following two groups:
Group A: Vaccination twice at 2-week intervals (n = 250) Group B: Vaccination twice at 4-week intervals (n = 250)
Fifty subjects in each group will receive placebos.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects who have obtained written consent voluntarily to participate in this clinical trial
- •Subjects whose age at the time of obtaining consent is 18 years or older
- •Subjects who are negative for SARS-CoV-2 by PCR test
- •Subjects who are negative for both SARS-CoV-2 IgM antibody and SARS-CoV-2 IgG antibody by antibody test
排除标准
- •Subjects with symptoms of suspected COVID-19 infection (respiratory symptoms, headache, malaise, olfactory disorders, taste disorders, etc.)
- •Subjects with a history of COVID-19 (hearing from subjects)
- •Subjects who have participated in unapproved vaccine clinical trials within 1 year before the start of this study
- •Subjects with axillary temperature of 37.0 degree or higher at the time of screening and before the first vaccination
- •Subjects who have a history of anaphylaxis
- •Subjects who have a history of hypersensitivity to the ingredients of the investigational drug
- •Subjects who have a current or history of serious renal, cardiovascular, respiratory, liver, kidney, gastrointestinal, and neuropsychiatric diseases
- •Subjects with a history of convulsion or epilepsy
- •Subjects with a history of diagnosis of immunodeficiency
- •Subjects who have a close relative (within 3rd degree) of congenital immunodeficiency
- •Subjects who have current bronchial asthma
- •Subjects who have had a fever of 39.0 degrees or higher within 2 days after vaccination, or who have been suspected of having an allergy such as a systemic rash.
- •Females who wish to become pregnant from the study registration to 12 weeks after the first vaccination, and pregnant females who are breast-feeding. In addition, females who may become pregnant and their male sexual partners should use appropriate contraceptives (pill), condoms, vasectomy, tubal ligation, diaphragm, intrauterine devices, spermicides, intrauterine hormone-releasing system, etc. from the study entry date until 12 weeks after the first vaccination
- •Subjects who have participated in clinical trials of other unapproved drugs and received the investigational drug within 4 weeks before the start of this clinical trial (starting from vaccination day)
- •Subjects who have been received a live vaccine, inactivated vaccine, or toxoid within 4 weeks before the start of this clinical trial (starting from vaccination day)
- •Subjects who have been administered with drugs that affect the immune system (excluding external preparations) such as immunomodulators (DMARDs, etc.), immunosuppressants, biologics, etc. within 4 weeks before vaccination
- •Subjects who received blood transfusion or gamma globulin therapy within 12 weeks before vaccination, or high-dose gamma globulin therapy (200 mg/kg or more) within 24 weeks before vaccination
- •Subjects who have a history of overseas travel within 4 weeks before the start of the clinical trial (starting from vaccination day)
- •Subjects who are unable to comply with the clinical trial protocol and follow up (for mental, family, social or geographical reasons)
- •Subjects who are judged to be ineligible for this clinical trial by the investigator
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events
时间窗: Group A: 6 weeks Group B: 8 weeks
Frequency and severity of each adverse event solicited local and systemic AEs from the first vaccination to 4 weeks after the second vaccination
Immunogenicity
时间窗: Group A: Week 7 Group B: Week 9
Change in Geometric mean titer (GMT) of serum anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody
次要结局
- Change in the neutralizing activity against pseudovirus of SARS-CoV-2(Group A: Weeks 5, 7, 25, 53 Group B: Weeks 7, 9, 25, 53)
- Change in GMT of anti-SARS-CoV-2 Spike (S) glycoprotein-specific antibody(Group A: Weeks 5, 25, 53 Group B: Weeks 7, 25, 53)
- Change in IFN-gamma production against SARS-CoV-2 spike (S) glycoprotein by T cells in peripheral blood mononuclear cells(Group A: Weeks 5, 7, 25, 53 Group B: Weeks 7, 9, 25, 53)
- IgG subclasses (IgG1 and IgG2) of anti-SARS-CoV-2 spike (S) glycoprotein-specific antibody(Group A: Weeks 5, 7, 25, 53 Group B: Weeks 7, 9, 25, 53)
- Adverse events(Group A: Week 7 through Week 53 Group B: Week 9 through Week 53)
- Rate of SARS-CoV-2 positive and incidence rate of COVID-19 after the first vaccination(Week 1 through Week 53)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
1 期
Study of COVID-19 DNA Vaccine (AG0302-COVID19)COVID-19NCT04527081AnGes, Inc.30
已完成
1 期
Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)COVID-19 Lower Respiratory InfectionNCT04993586AnGes, Inc.422
已完成
1 期
Study of COVID-19 DNA Vaccine (AG0301-COVID19)COVID-19NCT04463472AnGes, Inc.30
已完成
1 期
A Study of Ad26.COV2.S in Adults (COVID-19)Covid-19 PreventionNCT04436276Janssen Vaccines & Prevention B.V.1,085
已完成
2 期
A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African AdultsSARS-CoV-2 InfectionCOVID-19NCT04533399Novavax4,422